866-997-4948(US-Canada Toll Free)

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014

Published By :

Global Markets Direct

Published Date : Jul 2014

Category :

Cancer

No. of Pages : 313 Pages

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview 11
Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis 12
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies 13
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 17
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies 21
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes 24
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development 25
Johnson & Johnson 25
Sanofi 26
AstraZeneca PLC 27
Eli Lilly and Company 28
Viralytics Ltd. 29
Genentech, Inc. 30
Bavarian Nordic A/S 31
Emergent BioSolutions Inc. 32
Takeda Pharmaceutical Company Limited 33
Millennium Pharmaceuticals, Inc. 34
Novartis AG 35
GTx, Inc. 36
Ono Pharmaceutical Co., Ltd. 37
Teva Pharmaceutical Industries Limited 38
Progenics Pharmaceuticals, Inc. 39
Exelixis, Inc. 40
Celgene Corporation 41
Onyx Pharmaceuticals, Inc. 42
Merck KGaA 43
Active Biotech AB 44
Oncolytics Biotech Inc. 45
Medivation, Inc. 46
Synta Pharmaceuticals Corp. 47
Supratek Pharma Inc. 48
CellCentric Ltd. 49
CureVac GmbH 50
GenSpera, Inc. 51
BIND Therapeutics, Inc. 52
NewLink Genetics Corporation 53
Bellicum Pharmaceuticals, Inc. 54
AB Science 55
Adamis Pharmaceuticals Corporation 56
Karyopharm Therapeutics, Inc. 57
ATLAB Pharma SAS 58
AbbVie Inc. 59
Sotio a.s. 60
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Target 62
Assessment by Mechanism of Action 67
Assessment by Route of Administration 71
Assessment by Molecule Type 73
Drug Profiles 75
custirsen sodium - Drug Profile 75
tasquinimod - Drug Profile 78
enzalutamide - Drug Profile 80
cabozantinib s-malate - Drug Profile 83
rilimogene galvacirepvec - Drug Profile 86
masitinib - Drug Profile 88
cabazitaxel - Drug Profile 91
DCVAC/PCa - Drug Profile 93
patupilone - Drug Profile 95
abituzumab - Drug Profile 97
olaratumab - Drug Profile 99
navitoclax - Drug Profile 101
vandetanib - Drug Profile 103
PSMA ADC - Drug Profile 109
GTx-758 - Drug Profile 111
olaparib - Drug Profile 112
carfilzomib - Drug Profile 115
ganetespib - Drug Profile 119
pelareorep - Drug Profile 123
MLN-0128 - Drug Profile 127
dovitinib lactate - Drug Profile 129
CV-9103 - Drug Profile 132
G-202 - Drug Profile 134
docetaxel nanoparticles - Drug Profile 136
indoximod - Drug Profile 138
Adenovirus/PSA Vaccine - Drug Profile 140
CreaVax-PC - Drug Profile 141
TL-118 - Drug Profile 142
selinexor - Drug Profile 144
CV-9104 - Drug Profile 146
Dendritic Cell Therapy Targeting PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 147
ATL-101 - Drug Profile 148
Cell Therapy to Inhibit PSMA for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 150
TRC-105 - Drug Profile 151
AZD-5363 - Drug Profile 154
BPX-101 - Drug Profile 156
CC-115 - Drug Profile 158
CFG-920 - Drug Profile 159
Osteodex - Drug Profile 160
CVA-21 - Drug Profile 161
erismodegib - Drug Profile 165
nivolumab - Drug Profile 168
JNJ-56021927 - Drug Profile 172
RG-7450 - Drug Profile 174
AZD-5312 - Drug Profile 175
BPX-201 - Drug Profile 176
ONC-1-13B - Drug Profile 177
APC-200 - Drug Profile 178
APC-300 - Drug Profile 180
ES-414 - Drug Profile 181
Small Molecules to Inhibit Deubiquitinase for Castrate Resistant Prostate Cancer - Drug Profile 182
cabazitaxel nanoformulation - Drug Profile 183
Small Molecule To Antagonize Androgen Receptor For Prostate Cancer - Drug Profile 184
Small Molecules to Inhibit Bromodomain for Cancer - Drug Profile 185
Protein for Prostate Cancer - Drug Profile 186
Monoclonal Antibodies to Inhibit N-Cadherin for Bladder and Metastatic Hormone Refractory Prostate Cancers - Drug Profile 187
ABS-001 - Drug Profile 188
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Recent Pipeline Updates 189
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects 297
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products 298
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones 299
Featured News & Press Releases 299
Appendix 308
Methodology 308
Coverage 308
Secondary Research 308
Primary Research 308
Expert Panel Validation 308
Contact Us 309
Disclaimer 309

List of Tables
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2014 15
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2014 16
Number of Products under Development by Companies, H2 2014 18
Number of Products under Development by Companies, H2 2014 (Contd..1) 19
Number of Products under Development by Companies, H2 2014 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2014 21
Comparative Analysis by Late Stage Development, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Development, H2 2014 24
Products under Development by Companies, H2 2014 25
Products under Development by Companies, H2 2014 (Contd..1) 26
Products under Development by Companies, H2 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2014 28
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H2 2014 29
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sanofi, H2 2014 30
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca PLC, H2 2014 31
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2014 32
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd., H2 2014 33
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H2 2014 34
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 35
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H2 2014 36
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 37
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 38
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H2 2014 39
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H2 2014 40
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 41
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 42
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014 43
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Exelixis, Inc., H2 2014 44
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Celgene Corporation., H2 2014 45
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 46
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Merck KGaA, H2 2014 47
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Active Biotech AB, H2 2014 48
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 49
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H2 2014 50
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 51
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc., H2 2014 52
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd., H2 2014 53
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureVac GmbH, H2 2014 54
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GenSpera, Inc., H2 2014 55
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by BIND Therapeutics, Inc., H2 2014 56
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H2 2014 57
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2014 58
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AB Science, H2 2014 59
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2014 60
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 61
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2014 62
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc., H2 2014 63
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sotio a.s., H2 2014 64
Assessment by Monotherapy Products, H2 2014 65
Number of Products by Stage and Target, H2 2014 68
Number of Products by Stage and Mechanism of Action, H2 2014 73
Number of Products by Stage and Route of Administration, H2 2014 76
Number of Products by Stage and Molecule Type, H2 2014 78
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates, H2 2014 193
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H2 2014 301
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H2 2014 302

List of Figures
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2014 15
Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2014 16
Number of Products under Development by Companies, H2 2014 17
Number of Products under Investigation by Universities/Institutes, H2 2014 21
Comparative Analysis by Late Stage Development, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Products, H2 2014 24
Assessment by Monotherapy Products, H2 2014 65
Number of Products by Top 10 Target, H2 2014 66
Number of Products by Stage and Top 10 Target, H2 2014 67
Number of Products by Top 10 Mechanism of Action, H2 2014 71
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 72
Number of Products by Top 10 Route of Administration, H2 2014 75
Number of Products by Stage and Top 10 Route of Administration, H2 2014 76
Number of Products by Top 10 Molecule Type, H2 2014 77
Number of Products by Stage and Top 10 Molecule Type, H2 2014 78

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *